Related references
Note: Only part of the references are listed.A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Mary E. Rinella et al.
HEPATOLOGY (2023)
Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life
Zobair M. Younossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Prevalence of hypothyroidism and effect of thyroid hormone replacement therapy in patients with non-alcoholic fatty liver disease: A population-based study
Ashraf Almomani et al.
WORLD JOURNAL OF HEPATOLOGY (2022)
Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD
Maria Mavromati et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD
Andrea Caddeo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Pathophysiology of NASH in endocrine diseases
Karim Gariani et al.
ENDOCRINE CONNECTIONS (2021)
Thyroid function and non-alcoholic fatty liver disease in hyperthyroidism patients
Bairong Wang et al.
BMC ENDOCRINE DISORDERS (2021)
Exploring the Causality Between Hypothyroidism and Non-alcoholic Fatty Liver: A Mendelian Randomization Study
Shizheng Qiu et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany
Christian Labenz et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)
TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population
Alba Martinez-Escude et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH
Stephen A. Harrison et al.
HEPATOLOGY COMMUNICATIONS (2021)
Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)
Naim Alkhouri
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
Rohit A. Sinha et al.
HEPATOLOGY (2020)
Resting Energy Expenditure in Obese Women with Primary Hypothyroidism and Appropriate Levothyroxine Replacement Therapy
Emanuele Muraca et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Thyroid Hormone Signaling and the Liver
Megan J. Ritter et al.
HEPATOLOGY (2020)
Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options
Daniela Maria Tanase et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?
Amedeo Lonardo et al.
DIGESTIVE AND LIVER DISEASE (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair Younossi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD
Eveline Bruinstroop et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Global epidemiology of hyperthyroidism and hypothyroidism
Peter N. Taylor et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Thyroid Hormones, Thyromimetics and Their Metabolites in the Treatment of Liver Disease
Marta A. Kowalik et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis
Zeqi Guo et al.
DIGESTIVE AND LIVER DISEASE (2018)
Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Alessandro Mantovani et al.
THYROID (2018)
Reduced expression of thyroid hormone receptor β in human nonalcoholic steatohepatitis
Christin Krause et al.
ENDOCRINE CONNECTIONS (2018)
Action of Thyroid Hormones, T3 and T2, on Hepatic Fatty Acids: Differences in Metabolic Effects and Molecular Mechanisms
Fabrizio Damiano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Thyroid stimulating hormone increases hepatic gluconeogenesis via CRTC2
Yujie Li et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2017)
Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients
Lu Liu et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2017)
Relationship between Hypothyroidism and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Weiwei He et al.
FRONTIERS IN ENDOCRINOLOGY (2017)
Nonalcoholic Fatty Liver Disease Is Not Associated with Thyroid Hormone Levels and Hypothyroidism: A Systematic Review and Meta-Analysis
Veeravich Jaruvongvanich et al.
EUROPEAN THYROID JOURNAL (2017)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: a cross-sectional study of a random population sample aged 18 to 65 years
Ulla Ludwig et al.
BMC ENDOCRINE DISORDERS (2015)
Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome
Bo Angelin et al.
JOURNAL OF INTERNAL MEDICINE (2015)
Prevalence of hypothyroidism in nonalcoholic fatty liver disease in patients attending a tertiary hospital in western India
Pathik Parikh et al.
INDIAN JOURNAL OF GASTROENTEROLOGY (2015)
The Incidence and Prevalence of Thyroid Dysfunction in Europe: A Meta-Analysis
Ane Garmendia Madariaga et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans
Ylva Bonde et al.
JOURNAL OF LIPID RESEARCH (2014)
Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia
Martha J. Kelly et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The Effect of a Diiodothyronine Mimetic on Insulin Sensitivity in Male Cardiometabolic Patients: A Double-Blind Randomized Controlled Trial
Fleur van der Valk et al.
PLOS ONE (2014)
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study
Barbara Sjouke et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist
Rebecca Taub et al.
ATHEROSCLEROSIS (2013)
FoxO1 Deacetylation Regulates Thyroid Hormone-induced Transcription of Key Hepatic Gluconeogenic Genes
Brijesh Kumar Singh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Effects of the Thyromimetic Agent Diiodothyropropionic Acid on Body Weight, Body Mass Index, and Serum Lipoproteins: A Pilot Prospective, Randomized, Controlled Study
P. W. Ladenson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Carbohydrate Response Element Binding Protein Gene Expression Is Positively Regulated by Thyroid Hormone
Koshi Hashimoto et al.
ENDOCRINOLOGY (2009)
Activation of the hepatic LDL receptor promoter by thyroid hormone
Dayami Lopez et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)
Thyroid hormone receptor β-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats
Cassio M. Villicev et al.
JOURNAL OF ENDOCRINOLOGY (2007)
Molecular modeling of the thyroid hormone interactions with αvβ3 integrin
Vivian Cody et al.
STEROIDS (2007)
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone β receptor
F Furuya et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates:: Selective actions relative to 3,5,3′-triiodo-L-thyronine
GJ Grover et al.
ENDOCRINOLOGY (2004)
Share Paper
